|
| Press Releases |
|
 |
|
| Monday, June 3, 2024 |
|
|
Eisai Strengthens Venture Investment Business Aimed at Accelerating Drug Discovery Innovation and Establishment of Ecosystem Platform |
| Eisai Co., Ltd. announced today that the company decided to strengthen and continue its venture investment business, which launched in 2019, with the aim of discovering innovative technologies and services, supporting venture businesses with such technologies and partnering with those businesses in the future, so as to accelerate drug discovery innovation and the establishment of the ecosystem platform. more info >> |
|
|
エーザイ、TIME 誌による「最も影響力のある 100 社（TIME100 MOST INFLUENTIAL COMPANIES）」に選定 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、米国 TIME誌が選出する「TIME100 Most Influential Companies of 2024」に選定されたことをお知らせします。 more info >> |
|
|
エーザイ、創薬イノベーションおよびエコシステム プラットフォーム構築の加速に向けたベンチャー投資事業を強化 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、創薬イノベーションおよびエコシステム プラットフォーム構築の加速に向け、革新的技術やサービスの発掘とそれを有するベンチャー企業の支援、将来的な提携を目的とし、2019 年に開始したベンチャー投資事業を強化し、継続することを決定しましたのでお知らせします。 more info >> |
|
| Tuesday, May 28, 2024 |
|
|
LEQEMBI (lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Food and Drug Safety (MFDS) in South Korea has approved humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (lecanemab) for treatment in adult patients with mild cognitive impairment due to Alzheimer's disease (AD) or mild AD (early AD). more info >> |
|
| Thursday, May 23, 2024 |
|
|
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024 |
| Eisai Co., Ltd. announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24), which is taking place virtually and in-person in Chicago, Illinois from May 31 to June 4. more info >> |
|
| Wednesday, May 22, 2024 |
|
|
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Launched In Japan |
| Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac group announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate, "MTX"), in Japan. more info >> |
|
| Wednesday, May 15, 2024 |
|
|
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status |
| LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). more info >> |
|
| Monday, May 13, 2024 |
|
|
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures |
| Eisai Co., Ltd. announced today that it has received approval in China for the additional indication of its in-house discovered antiepileptic drug (AED) Fycompa (generic name: perampanel hydrate) for adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older. more info >> |
|
| Thursday, April 18, 2024 |
|
|
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) |
| Eisai Co., Ltd. announced today that "The Research on Treatments for Alzheimer's Disease Based on its Pathological Mechanisms" has received the Award for Science and Technology (Research Category) as a part of the FY2024 Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology. more info >> |
|
| Wednesday, April 17, 2024 |
|
|
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan |
| Eisai Co., Ltd. announced today that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) for intravenous (IV) infusion has been launched in Japan. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Yee Hop Holdings (1662.HK) Subsidiary APEL Launches Microfactory in Collaboration with HKPC
Jun 13, 2025 20:38 HKT/SGT
|
|
|
SAP商業AI持續釋放數據價值 驅動企業韌性增長
Jun 13, 2025 20:33 HKT/SGT
|
|
|
義合控股(1662.HK)附屬APEL與生產力局攜手打造智能微工廠正式投產
Jun 13, 2025 20:20 HKT/SGT
|
|
|
义合控股(1662.HK)附属APEL与生产力局携手打造智能微工厂正式投产
Jun 13, 2025 19:42 HKT/SGT
|
|
|
Jacobson Pharma Announces FY2025 Annual Results
Jun 13, 2025 19:16 HKT/SGT
|
|
|
雅各臣公佈二零二五財年全年業績 持續經營業務溢利飈升43.1％至3.0億港元
Jun 13, 2025 19:06 HKT/SGT
|
|
|
Desert Mirage or Musical Revolution? ESCAPE Records' Secret Vault Opens, Revealing a Hidden Sonic Sanctuary
Jun 13, 2025 19:00 HKT/SGT
|
|
|
雅各臣公布二零二五财年全年业绩 持续经营业务溢利飙升43.1％至3.0亿港元
Jun 13, 2025 18:53 HKT/SGT
|
|
|
Ria Money Transfer's New Approval Enables Digital Salary Payments for Malaysia's Migrant Workforce
Jun 13, 2025 13:00: JST
|
|
|
ARE Expands India Leadership, Strengthens Regional Role in Climate, Energy, and Food System Transition
Jun 13, 2025 12:46: JST
|
|
|
Ria Money Transfer's New Approval Enables Digital Salary Payments for Malaysia's Migrant Workforce
Jun 13, 2025 12:00 HKT/SGT
|
|
|
TRENDE Announces Strategic Capital and Business Alliance with Tokyu Land
Jun 13, 2025 13:00 JST
|
|
|
ARE Expands India Leadership, Strengthens Regional Role in Climate, Energy, and Food System Transition
Jun 13, 2025 11:46 HKT/SGT
|
|
|
JBM Healthcare Delivers Strong FY2025 Annual Results, Net Profit Surged 51.2% to HK$197.3 Million
Jun 12, 2025 21:07 HKT/SGT
|
|
|
健倍苗苗二零二五財年全年業績表現亮眼 純利飆升51.2%至1.97億港元
Jun 12, 2025 20:58 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
